Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | BRD4 | O60885 | 1/20 | 0.51 |
| ▸ | MPO | P05164 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | PDK1 | Q15118 | 4/20 | 0.45 |
| ▸ | PDK2 | Q15119 | 4/20 | 0.45 |
| ▸ | PDK3 | Q15120 | 4/20 | 0.45 |
| ▸ | PDK4 | Q16654 | 4/20 | 0.45 |
| ▸ | SRD5A1 | P18405 | 1/20 | 0.43 |
| ▸ | CA1 | P00915 | 1/20 | 0.43 |
| ▸ | CA2 | P00918 | 1/20 | 0.43 |
| ▸ | CA9 | Q16790 | 1/20 | 0.43 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.43 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19689700 | 0.92 | GPR119 (0.47) | KDM4EALDH1A1HSD17B10SRD5A1NOTUM | |
| SCHEMBL380901 | 0.91 | KDM4E (0.53) | KDM4EBRD4MPOALDH1A1HSD17B10 | |
| SCHEMBL30076622 | 0.91 | KDM4E (0.53) | KDM4EBRD4MPOALDH1A1HSD17B10 | |
| SCHEMBL6625750 | 0.90 | LMNA (0.46) | KDM4EBRD4MPOALDH1A1MEN1 | |
| SCHEMBL6646790 | 0.88 | KDM4E (0.48) | KDM4EBRD4MPOALDH1A1HSD17B10 | |
| SCHEMBL6646791 | 0.88 | KDM4E (0.48) | KDM4EBRD4MPOALDH1A1HSD17B10 | |
| SCHEMBL380505 | 0.84 | DHODH (0.49) | KDM4EBRD4MPOALDH1A1HSD17B10 | |
| SCHEMBL30527088 | 0.84 | DHODH (0.49) | KDM4EBRD4MPOALDH1A1HSD17B10 | |
| SCHEMBL30674388 | 0.84 | ESR2 (0.55) | KDM4EBRD4MPOHSD17B10PDK1 | |
| SCHEMBL21428260 | 0.84 | KDM4E (0.73) | KDM4EBRD4MPOALDH1A1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1326611-A4 | AZA- AND POLYAZA-NAPHTHALENYL-CARBOXAMIDES USEFUL AS HIV INTEGRASE INHIBITORS | MERCK & CO INC (US) | 2004-04-07 | — | — | EP | claimed |
| EP-1326611-A1 | AZA- AND POLYAZA-NAPHTHALENYL-CARBOXAMIDES USEFUL AS HIV INTEGRASE INHIBITORS | Merck & Co., Inc. (US) | 2003-07-16 | — | — | EP | claimed |
| EP-1326865-A2 | AZA- AND POLYAZA-NAPHTHALENYL CARBOXAMIDES USEFUL AS HIV INTEGRASE INHIBITORS | Merck & Co., Inc. (US) | 2003-07-16 | — | — | EP | claimed |
| WO-2002030426-A1 | AZA- AND POLYAZA-NAPHTHALENYL-CARBOXAMIDES USEFUL AS HIV INTEGRASE INHIBITORS | MERCK & CO., INC. (US) | 2002-04-18 | — | — | WO | claimed |
| WO-2002030930-A2 | AZA- AND POLYAZA-NAPHTHALENYL CARBOXAMIDES USEFUL AS HIV INTEGRASE INHIBITORS | MERCK & CO., INC. (US) | 2002-04-18 | — | — | WO | claimed |
| US-6831080-B2 | E.g., 3-(2-fluorophenyl)-N-(1-(3-morpholin-4-yl)phenyl)-propyl)acrylamide; disorders responsive to opening of KCNQ potassium channels; analgesics; migraine, bipolar disorders, anticonvulsants, antiepileptic, anxiolytic agents | BRISTOL-MYERS SQUIBB COMPANY | 2004-12-14 | — | — | US | disclosed |
| EP-1326611-A4 | AZA- AND POLYAZA-NAPHTHALENYL-CARBOXAMIDES USEFUL AS HIV INTEGRASE INHIBITORS | MERCK & CO INC (US) | 2004-04-07 | — | — | EP | disclosed |
| EP-1392644-A1 | CINNAMIDE DERIVATIVES AS KCNQ POTASSIUM CHANNEL MODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-03-03 | — | — | EP | disclosed |
| US-20030166650-A1 | Cinnamide derivatives as KCNQ potassium channel modulators | BRISTOL-MYERS SQUIBB COMPANY | 2003-09-04 | — | — | US | disclosed |
| EP-1333831-A2 | AZA-AND POLYAZA-NAPHTHALENYL KETONES USEFUL AS HIV INTEGRASE INHIBITORS | Merck & Co., Inc. (US) | 2003-08-13 | — | — | EP | disclosed |
| EP-1326611-A1 | AZA- AND POLYAZA-NAPHTHALENYL-CARBOXAMIDES USEFUL AS HIV INTEGRASE INHIBITORS | Merck & Co., Inc. (US) | 2003-07-16 | — | — | EP | disclosed |
| EP-1326865-A2 | AZA- AND POLYAZA-NAPHTHALENYL CARBOXAMIDES USEFUL AS HIV INTEGRASE INHIBITORS | Merck & Co., Inc. (US) | 2003-07-16 | — | — | EP | disclosed |
| WO-2002096858-A1 | CINNAMIDE DERIVATIVES AS KCNQ POTASSIUM CHANNEL MODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2002-12-05 | — | — | WO | disclosed |
| WO-2002036734-A2 | AZA-AND POLYAZA-NAPHTHALENYL KETONES USEFUL AS HIV INTEGRASE INHIBITORS | MERCK & CO., INC. (US) | 2002-05-10 | — | — | WO | disclosed |
| WO-2002030426-A1 | AZA- AND POLYAZA-NAPHTHALENYL-CARBOXAMIDES USEFUL AS HIV INTEGRASE INHIBITORS | MERCK & CO., INC. (US) | 2002-04-18 | — | — | WO | disclosed |
| WO-2002030930-A2 | AZA- AND POLYAZA-NAPHTHALENYL CARBOXAMIDES USEFUL AS HIV INTEGRASE INHIBITORS | MERCK & CO., INC. (US) | 2002-04-18 | — | — | WO | disclosed |
| WO-2002030931-A2 | AZA- AND POLYAZA-NAPHTHALENYL CARBOXAMIDES USEFUL AS HIV INTEGRASE INHIBITORS | MERCK & CO., INC. (US) | 2002-04-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030166650-A1 | Cinnamide derivatives as KCNQ potassium channel modulators | KCNH2, KCNH3, KCNQ1 | KDM4E 485/4885BRD4 909/4885MPO 3650/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.